Navigation Links
Children's Hospital physicians publish review of transplant issues in patients with biliary atresia
Date:1/8/2008

The most common indication worldwide for pediatric transplantation, biliary atresia is also the most common cause of chronic liver disease in newborns. Recently, Childrens Hospital of Pittsburgh of UPMC physicians completed a review of issues that children with biliary atresia face that lead to the need for transplantation.

Nationally about 42 percent of children undergoing their first liver transplant are diagnosed with biliary atresia. Through the review, which is published in the November issue of Liver Transplantation, doctors at Childrens propose that carefully planned medical management of children with biliary atresia is essential to minimize morbidity and mortality. Optimal outcomes for liver transplantation are reached by carefully examining indications for and alternative to transplantation and through the management of clinical problems for children with biliary atresia.

Careful assessment of the clinical status of children with biliary atresia is essential, said co-author Benjamin L. Shneider, MD, director, Pediatric Hepatology Program at Childrens. It is so important to optimize medical and surgical management and carefully determine the timing for liver transplantation, if it is needed.

At Childrens, 308 primary liver transplants were performed between 1995 and 2006. Of these, 103, or 33 percent, were performed for biliary atresia. Overall patient survival and graft survival rates at more than 10 years were 88 percent and 81 percent, respectfully, among the highest long term survival rates in the world. These patients were enrolled in the Studies on Pediatric Liver Transplantation (SPLIT) --- a multi-center, prospective study to collect scientific data on pediatric liver transplantation.

Surgical outcomes after liver transplantation for biliary atresia are outstanding in spite of complex anatomic issues and the small size of many of our patients, said co-author George Mazarigeos, MD, director of the Hillman Center for Pediatric Transplantation. By using a full complement of surgical techniques, an experienced center can minimize mortality for children awaiting transplantation. In addition, this can lead to excellent long-term outcomes.

Biliary atresia, which occurs once in every 15,000 births, is an irreversible problem that is fatal without treatment. However, surgical intervention (the Kasai hepatoportoenterostomy) may allow a child with biliary atresia to live longer and have a better quality of life. In order to have optimal results, infants should undergo surgery before 2 months of age, necessitating early referral. Symptoms of biliary atresia occur between 2 weeks to 2 months of life, and may include: jaundice that persists beyond 3 weeks of age, dark urine, light colored stools and failure to thrive.


'/>"/>

Contact: Marc Lukasiak
marc.lukasiak@chp.edu
412-692-7919
Children's Hospital of Pittsburgh
Source:Eurekalert

Related medicine news :

1. Nautica Malibu Triathlon Presented by Toyota Raises $718,000 for Childrens Hospital Los Angeles Pediatric Cancer Research
2. Childrens Hospital Los Angeles Turns Off the Tap With Green Earth Waterless Carwash
3. New research explores newborn in-hospital weight loss
4. NYC-area 1st: Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement
5. Norwalk virus: Cruise ship illness challenging and costly to hospitals, too
6. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
7. Billy Graham Home After Hospitalization:
8. Alvarado Hospital Files Countersuit Against Blue Shield
9. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
10. Texas Supreme Court Rules Against Medicare HMOs in Hospital Reimbursement Fight
11. Annual flu shot cuts need for doctors visits, hospitalization among children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has issued an ... extreme heat at their worksites. Employers with workers exposed to high temperatures ...
(Date:6/27/2016)... ... 27, 2016 , ... "FCPX editors can now reveal their media with growing ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings ... users can now reveal the media of their split screens with growing colorful panels. ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced its strategic partnership with Connance, a healthcare industry leader providing predictive ... proven, proprietary technology combine to provide health systems, hospitals and ambulatory surgical ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... SYDNEY , June 26, 2016 One of ... , has announced the formation of a new biotechnology company, Noxopharm ... raise $6m in an IPO and to list on the ASX. ... drug candidate, NOX66, ready to enter a Phase 1 clinical study ... been designed to address one of the biggest problems facing cancer ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: